|
Objectives
To study the determinants of long-term (lung fibrosis)
outcomes in patients with SARS.
To evaluate the risk of virus long-term excretion
in recovered patients,
To validate data collection forms (epidemiological,
clinical, and biological) for use in hospitals in case of future
SARS outbreaks.
Description of work
Task 1: Two cohorts of
convalescent patients are available for studies as part of this
project: one linked to department of Infectious Diseases at the
PUMC Hospital, and one at the General Hospital of Beijing Armed
Police. Both cohorts include clinical and epidemiological data at
intake. They differ by the type of biological samples available
at a later stage:
- the PUMC Hospital cohort has sequential plasma
and PBMC samples from the acute phase on 100 patients and every
month thereafter on about 60 subjects,
- the General Hospital of Beijing Armed Police Hospital cohort
has sequential blood / throat / faeces / urine samples kept at
-20°C / -80°C from 70 subjects.
Follow-up is planned every three months for 2 years.
Long-term clinical outcome (detailed assessment of lung functions)
will be studied in both cohorts.
Task 2: Early clinical
and biological data will be used to study the risk factors for poor
short-term (transfer to intensive care units and death) and long-term
(lung fibrosis) outcomes in these two cohorts of patients. Long-term
excretion of SARS-CoV (in urines and stools by RT-PCR method, and
viral isolation if PCR-positive) will be examined.
Task 3: A critical analysis
of data collected during the first epidemic among hospitalised patients
will be performed to improve data collection forms in case of a
new epidemic.
Deliverables
D37 Risk factors long-term clinical outcome based
in initial assessment and follow-up.
D38 Incidence and infectiousness of long-term
viral excretion in patients with SARS.
D39 Improved data collection forms for use in
hospital in case of a new epidemic.
Milestones and expected result
M0-M6: prepare adequate databases
and review of the respitory tests performed at month 12 after the
onset of the disease
M6-M12: interim analysis on risk factors for poor
clinical outcome after the first year of follow-up
M6-M18: analysis of long-term viral excretion
in recovered patients within the first year of follow-up
M15-M30: synthesis of the results and preparation
fo manuscripts
Expected results: better knowledge of long-term clinical outcome
of patients with SARS, evaluation of the risk for long term viral
excretion in the community
|
